[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated : Reports First Quarter 2025 Financial Results ( reports first quarter 2025 financial results)",
    "summary": "May 5, 2025-- Vertex Pharmaceuticals Incorporated today reported cons...",
    "url": "https://finnhub.io/api/news?id=da21ddd7f5aa8a5ca7526bf16ed3d7b74f165da949b73cbc4b10b6ba6b9eb9b0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746482608,
      "headline": "Vertex Pharmaceuticals Incorporated : Reports First Quarter 2025 Financial Results ( reports first quarter 2025 financial results)",
      "id": 134252427,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "May 5, 2025-- Vertex Pharmaceuticals Incorporated today reported cons...",
      "url": "https://finnhub.io/api/news?id=da21ddd7f5aa8a5ca7526bf16ed3d7b74f165da949b73cbc4b10b6ba6b9eb9b0"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated 2025 Q1 - Results - Earnings Call Presentation",
    "summary": "The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2025 Q1 earnings call.",
    "url": "https://finnhub.io/api/news?id=d8b413c6130fd38d68ee72719599a777076da7523002efde19bd1641f9ee8ec2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746481228,
      "headline": "Vertex Pharmaceuticals Incorporated 2025 Q1 - Results - Earnings Call Presentation",
      "id": 134252345,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2025 Q1 earnings call.",
      "url": "https://finnhub.io/api/news?id=d8b413c6130fd38d68ee72719599a777076da7523002efde19bd1641f9ee8ec2"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Misses Q1 Earnings and Revenue Estimates",
    "summary": "Vertex (VRTX) delivered earnings and revenue surprises of -3.79% and 1.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=2d8ecf87168eee4f1ef607fb655cb2e63883bd195c5ff3d34ae8d393953e4b54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746479707,
      "headline": "Vertex Pharmaceuticals (VRTX) Misses Q1 Earnings and Revenue Estimates",
      "id": 134266551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) delivered earnings and revenue surprises of -3.79% and 1.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=2d8ecf87168eee4f1ef607fb655cb2e63883bd195c5ff3d34ae8d393953e4b54"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Sales Below Analyst Estimates In Q1 Earnings",
    "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue guidance of $11.88 billion at the midpoint came in 0.9% below analysts’ estimates. Its non-GAAP profit of $4.06 per share was 5.4% below analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=e926d0c2f3a2d3450d9c8373b6ff4390c3348a32f1c3383c9d2de145aa0c14e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746478018,
      "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Sales Below Analyst Estimates In Q1 Earnings",
      "id": 134266552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue guidance of $11.88 billion at the midpoint came in 0.9% below analysts’ estimates. Its non-GAAP profit of $4.06 per share was 5.4% below analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=e926d0c2f3a2d3450d9c8373b6ff4390c3348a32f1c3383c9d2de145aa0c14e0"
    }
  },
  {
    "ts": null,
    "headline": "Vertex misses quarterly results on weaker-than-expected sales for cystic fibrosis drug",
    "summary": "(Reuters) -Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% after the bell.  BMO Capital Markets analyst Evan Seigerman said the revenue miss is likely to draw scrutiny, as Vertex needs to execute the launch of Journavx.  In December, the U.S. Food and Drug Administration approved Vertex's next-generation treatment, Alyftrek.",
    "url": "https://finnhub.io/api/news?id=a1c14f9d5bc3736c29911fa78a079f43d5213971e1550a708ad918005307f284",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746476279,
      "headline": "Vertex misses quarterly results on weaker-than-expected sales for cystic fibrosis drug",
      "id": 134266553,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "(Reuters) -Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% after the bell.  BMO Capital Markets analyst Evan Seigerman said the revenue miss is likely to draw scrutiny, as Vertex needs to execute the launch of Journavx.  In December, the U.S. Food and Drug Administration approved Vertex's next-generation treatment, Alyftrek.",
      "url": "https://finnhub.io/api/news?id=a1c14f9d5bc3736c29911fa78a079f43d5213971e1550a708ad918005307f284"
    }
  },
  {
    "ts": null,
    "headline": "Vertex: Q1 Earnings Snapshot",
    "summary": "On a per-share basis, the Boston-based company said it had net income of $2.49. Earnings, adjusted for one-time gains and costs, came to $4.06 per share. The results did not meet Wall Street expectations.",
    "url": "https://finnhub.io/api/news?id=85dbeb8b55b6c87a0729b9ec6395133337a66446c1822acf0e7d2deae9734548",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746475769,
      "headline": "Vertex: Q1 Earnings Snapshot",
      "id": 134266554,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "On a per-share basis, the Boston-based company said it had net income of $2.49. Earnings, adjusted for one-time gains and costs, came to $4.06 per share. The results did not meet Wall Street expectations.",
      "url": "https://finnhub.io/api/news?id=85dbeb8b55b6c87a0729b9ec6395133337a66446c1822acf0e7d2deae9734548"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call Transcript",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ETCompany ParticipantsSusie Lisa - SVP, IRReshma...",
    "url": "https://finnhub.io/api/news?id=54b6d603b99f4b08054b6faa30348b849859f37e2e31c3934a9e7c68f718ff29",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746475267,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call Transcript",
      "id": 134251997,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ETCompany ParticipantsSusie Lisa - SVP, IRReshma...",
      "url": "https://finnhub.io/api/news?id=54b6d603b99f4b08054b6faa30348b849859f37e2e31c3934a9e7c68f718ff29"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Reports First Quarter 2025 Financial Results",
    "summary": "BOSTON, May 05, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2025, and raised the low end of its total revenue guidance range by $100 million, from $11.75 billion to $12 billion to a new range of $11.85 billion to $12 billion.",
    "url": "https://finnhub.io/api/news?id=e9d68997e48a02ec735b94d5873e035a0190b14a7e3e2e4fa7216fc553e75afe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746475260,
      "headline": "Vertex Reports First Quarter 2025 Financial Results",
      "id": 134266555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, May 05, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2025, and raised the low end of its total revenue guidance range by $100 million, from $11.75 billion to $12 billion to a new range of $11.85 billion to $12 billion.",
      "url": "https://finnhub.io/api/news?id=e9d68997e48a02ec735b94d5873e035a0190b14a7e3e2e4fa7216fc553e75afe"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Posts Q1 Adjusted EPS Of $4.06",
    "summary": "Vertex Pharmaceuticals Inc: * VERTEX PHARMACEUTICALS Q1 ADJUSTED EPS $4.06 VERSUS IBESESTIMATE $4.32 * VERTEX PHARMACEUTICALS Q1 TOTAL REVENUE $2.77 BILLIONVERSUSIBES...",
    "url": "https://finnhub.io/api/news?id=536b0666e3560313a741665cd4a808f2c4d306c9b0eafca5648e2a059149bbbe",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746467702,
      "headline": "Vertex Pharmaceuticals Posts Q1 Adjusted EPS Of $4.06",
      "id": 134251523,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "Vertex Pharmaceuticals Inc: * VERTEX PHARMACEUTICALS Q1 ADJUSTED EPS $4.06 VERSUS IBESESTIMATE $4.32 * VERTEX PHARMACEUTICALS Q1 TOTAL REVENUE $2.77 BILLIONVERSUSIBES...",
      "url": "https://finnhub.io/api/news?id=536b0666e3560313a741665cd4a808f2c4d306c9b0eafca5648e2a059149bbbe"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge",
    "summary": "By Paul Ziobro Vertex Pharmaceuticals reported a slight increase in first-quarter sales, while profit fell due to higher operating expenses and an impairment charge tied to the discontinuation of...",
    "url": "https://finnhub.io/api/news?id=d6a9ef95f86b49123326993e457b7f07ccbac0c32a7afb2292df7e987c3949f0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746464468,
      "headline": "Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge",
      "id": 134251281,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "By Paul Ziobro Vertex Pharmaceuticals reported a slight increase in first-quarter sales, while profit fell due to higher operating expenses and an impairment charge tied to the discontinuation of...",
      "url": "https://finnhub.io/api/news?id=d6a9ef95f86b49123326993e457b7f07ccbac0c32a7afb2292df7e987c3949f0"
    }
  },
  {
    "ts": null,
    "headline": "Vertex misses quarterly results on weaker-than-expected demand for cystic fibrosis drug",
    "summary": "Vertex Pharmaceuticals missedWall Street estimates for quarterly results on Monday, due tolower-than-expected sales of its cystic fibrosis drugTrikafta. However, the drugmaker raised...",
    "url": "https://finnhub.io/api/news?id=1c337d7e3d80297d1ce7b52fda59d0e06eb317936a5670d047a1815597dbea8e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746461251,
      "headline": "Vertex misses quarterly results on weaker-than-expected demand for cystic fibrosis drug",
      "id": 134250887,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "Vertex Pharmaceuticals missedWall Street estimates for quarterly results on Monday, due tolower-than-expected sales of its cystic fibrosis drugTrikafta. However, the drugmaker raised...",
      "url": "https://finnhub.io/api/news?id=1c337d7e3d80297d1ce7b52fda59d0e06eb317936a5670d047a1815597dbea8e"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Selloff: 4 No-Brainer Stocks to Buy Right Now",
    "summary": "Now may be a smart time to buy small stakes in these fundamentally robust companies.",
    "url": "https://finnhub.io/api/news?id=e86eafbe6dc5d3aca6b715021b41cf1da6fd82da70711b620e2e6b3ae1b2f675",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746442800,
      "headline": "Stock Market Selloff: 4 No-Brainer Stocks to Buy Right Now",
      "id": 134246764,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Now may be a smart time to buy small stakes in these fundamentally robust companies.",
      "url": "https://finnhub.io/api/news?id=e86eafbe6dc5d3aca6b715021b41cf1da6fd82da70711b620e2e6b3ae1b2f675"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts",
    "summary": "CRISPR Therapeutics and Intellia face 2025 volatility, but CRSPâs strong cash and launches make it more attractive than NTLA. Learn more on CRSP and NTLA stocks here.",
    "url": "https://finnhub.io/api/news?id=c3e2cd5c08e868d6823d9a2dffcfbbd2e24a2da1fbb8bb813c825b626f36f2fc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746420296,
      "headline": "CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts",
      "id": 134244299,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/694177344/image_694177344.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "CRISPR Therapeutics and Intellia face 2025 volatility, but CRSPâs strong cash and launches make it more attractive than NTLA. Learn more on CRSP and NTLA stocks here.",
      "url": "https://finnhub.io/api/news?id=c3e2cd5c08e868d6823d9a2dffcfbbd2e24a2da1fbb8bb813c825b626f36f2fc"
    }
  }
]